

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029577 A2(51) International Patent Classification⁷:

G01N

(74) Agents: SHEEHAN, John, M. et al.; FMC Corporation,
1735 Market Street, Philadelphia, PA 19103 (US).

(21) International Application Number:

PCT/US2003/029901

(22) International Filing Date:

18 September 2003 (18.09.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/413,720

26 September 2002 (26.09.2002)

US

(71) Applicant (for all designated States except US): FMC
CORPORATION [US/US]; 1735 Market Street, Philadel-
phia, PA 19103 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHEN, Ruihua
[CN/US]; 16 Labrador Drive, Kendall Park, NJ 08824
(US). CHAGUTURU, Munirathnam, K. [US/US]; 3
Edith Court, West Windsor, NJ 08550 (US). YUHAS,
Debra [US/US]; 622 Hanover Drive, Wrightstown, NJ
08562 (US). ALLENZA, Paul [US/US]; 16 Pleasant View
Way, Flemington, NJ 08822 (US). HALLING, Blaik, P.
[US/US]; 384 Chase Road, Newtown, PA 18940 (US).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**Published:**— without international search report and to be republished
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HEMIPTERAN MYOSIN LIGHT CHAIN KINASE

(57) Abstract: Novel nucleic acid sequences encoding hemipteran myosin light chain kinases are disclosed. Isolated hemipteran myosin light chain kinases are also disclosed.

BEST AVAILABLE COPY

WO 2004/029577 A2

HEMIPTERAN MYOSIN LIGHT CHAIN KINASE

Field of the Invention

5 The present invention relates to compositions that are useful in agrochemical, veterinary or pharmaceutical fields. In particular, the invention relates to polypeptides and nucleotide sequences that encode polypeptides that are useful in the identification or development of compounds with activity as pesticides or as pharmaceuticals.

Background of the Invention

10 Myosin light chain kinase (MLCK) is believed to play an important role in regulating muscle activity. Namely, it is suspected that phosphorylation of myosin light chain (MLC) by MLCK is required for the initiation of muscle contraction, including cardiac muscle contraction (Kasturi et al., J. of Bio. Chem. (1993), Vol. 268, No. 11, pp. 7958-7964; Lei et al., J. of Bio. Chem. (1994), Vol. 269, No. 33, pp. 21078-21085; Heierhorst et al., J. of Bio. Chem. (1994), Vol. 269, No. 33, pp. 21086-21093; and Weitkamp al., J. of Bio. Chem. (1998), Vol. 273, No. 31, pp. 19802-19808). Hence, interruption or inhibition of the MLCK phosphorylation of MLC can result in various biological effects (Kasturi et al., J. of Bio. Chem. (1993), Vol. 268, No. 11, pp. 7958-7964; Lei et al., J. of Bio. Chem. (1994), Vol. 269, No. 33, pp. 21078-21085; Heierhorst et al., J. of Bio. Chem. (1994), Vol. 269, No. 33, pp. 21086-21093; and Weitkamp al., J. of Bio. Chem. (1998), Vol. 273, No. 31, pp. 19802-19808). As such, there is a desire to develop ways to target this enzyme as a means of identifying biologically active compounds, including insecticides.

25 Twitchin, derived from *unc-22* mutants of *C. elegans*; projectin, derived from *Drosophila melanogaster*; and titin, are well known MLCKs (Daley et al., J. Mol. Bio. (1998), 279, pp. 201-210; and Hardie and Hanks, The Protein Kinase FactsBook (1995), pp. 161-165). Twitchin- and projectin-like MLCKs have also been expressed and cloned from bacteria, for example *E. coli*, molluscs, for example, *Aplysia californica*, and insects, for example, *Bombyx mori* and *Locusta migratoria* (Lei et al., J. of Bio. Chem. (1994), Vol. 269, No. 33, pp. 21078-21085;

Heierhorst et al., J. of Bio. Chem. (1994), Vol. 269, No. 33, pp. 21086-21093;
Weitkamp al., J. of Bio. Chem. (1998), Vol. 273, No. 31, pp. 19802-19808; and
NCBI Sequence Viewer, Accession Numbers AF465600, AF4656001, and
AF4656002).

5

Summary of the Invention

The present invention relates to nucleotide sequences that encode
polypeptides that are useful in the identification or development of compounds
with activity as pesticides or as pharmaceuticals. The present invention also relates
to polypeptide sequences that are useful in the identification or development of
10 compounds with activity as pesticides or as pharmaceuticals. These nucleotide
sequences and polypeptide sequences, will also be referred to herein as "*nucleotide
sequences of the invention*" and "*polypeptide sequences of the invention*",
respectively

Definitions

15

Collectively, the nucleic acids of the present invention will be referred to
herein as "*nucleic acids of the invention*". Also, where appropriate in the context
of the further description of the invention below, the terms "*nucleotide sequence of
the invention*" and "*nucleic acid of the invention*" may be considered essentially
equivalent and essentially interchangeable.

20

Also, for the purposes of the present invention, a nucleic acid is considered
to be "*(in) essentially isolated (form)*" – for example, from its native biological
source - when it has been separated from at least one other nucleic acid molecule
and sequence with which it is usually associated. Similarly, a polypeptide is
considered to be "*(in) essentially isolated (form)*" – for example, from its native
25 biological source - when it has been effectively separated from other polypeptide
molecules with which it is normally associated with. In particular, a nucleic acid
or polypeptide is considered "*essentially isolated*" when it has been purified at
least 2-fold, in particular at least 10-fold, more in particular at least 100-fold, and
up to 1000-fold or more.

30

Detailed Description of the Invention

The present invention relates to a nucleic acid, preferably in essentially
isolated form, which nucleic acid comprises a nucleotide sequence of the

invention, and in particular the nucleotide sequences of SEQ ID NO: 1. The present invention also relates to a polypeptide sequence of the invention, and in particular the polypeptide sequences of SEQ ID NO: 2. The nucleotide sequences of SEQ ID NO: 1 was derived or isolated from the *Aphis gossypii* organism, in the manner as further described in the Experimental Part below. The polypeptide sequence of SEQ ID NO: 2 is encoded by nucleic acid having SEQ ID NO: 1.

Generally, the nucleotide sequences of the invention, when in the form of a nucleic acid, may be DNA or RNA, and may be single stranded or double stranded. For example, the nucleotide sequences of the invention may be genomic DNA, cDNA or synthetic DNA (such as DNA with a codon usage that has been specifically adapted for expression in the intended host cell or host organism, which may for instance be designed using suitable computer programs such as Oligo-4, available from National Biosciences, Inc. (Plymouth, MN) and Consensus-Degenerate Hybrid Oligonucleotide Primers Software (CODEHOP) from Henikoff et al. (*Nucleic Acids Research*, 26, 70, 1628-1635, 1998) available on line through the Fred Hutchinson Cancer Research Center. Thus, the nucleotide sequences of the invention may contain intron sequences, and also generally comprise different splice variants.

Yet another embodiment relates to a double stranded RNA molecule directed against a nucleotide sequence of the invention (one strand of which will usually comprise at least part of a nucleotide sequence of the invention). The invention also relates to genetic constructs that can be used to provide such double stranded RNA molecules (e.g. by suitable expression in a host cell or host organism, or for example in a bacterial strain such as *E.coli*). For such constructs, reference is made to Maniatis et al., *Molecular Cloning, a Laboratory Manual* (Cold Spring Harbor Press, 1989).

In a broader sense, the term "nucleotide sequence of the invention" also comprises:

- parts or fragments of the nucleotide sequences of SEQ ID NO: 1
- (natural or synthetic) mutants, variants, alleles, analogs, orthologs (herein below collectively referred to as "mutants") of the nucleotide sequences of SEQ ID NO: 1 as further described below.

- parts or fragments of such (natural or synthetic) mutants;
- nucleotide fusions of the nucleotide sequences of SEQ ID NO: 1 (or a part or fragment thereof) with at least one further nucleotide sequence;
- nucleotide fusions of (natural or synthetic) mutants (or a part or fragment thereof) with at least one further nucleotide sequence;

in which such mutants, parts, fragments or fusions are preferably as further described below.

The invention also comprises different splice variants of the above nucleotide sequences.

- 10 Preferably, a nucleotide sequence of the invention will have a length of at least 500 nucleotides, preferably at least 1,000 nucleotides, more preferably at least 1,500 nucleotides; and up to a length of at most 3,500 nucleotides, preferably at most 3,000 nucleotides, more preferably at most 2,600 nucleotides.

- 15 In a broader sense, the term "*polypeptide sequence of the invention*" also comprises:

- parts or fragments of the polypeptide sequences of SEQ ID NO: 2;
 - (natural or synthetic) mutants, variants, alleles, analogs, orthologs (herein below collectively referred to as "*mutants*") of the polypeptide sequences of SEQ ID NO: 2.
- 20 - parts or fragments of such (natural or synthetic) mutants;
- peptide fusions of the polypeptide sequences of SEQ ID NO: 2 (or a part or fragment thereof) with at least one further polypeptide sequence;
 - peptide fusions of (natural or synthetic) mutants (or a part or fragment thereof) with at least one further polypeptide sequence;

25

- Examples of parts or fragments of the nucleotide sequences of SEQ ID NO: 1 or a part or fragment of a (natural or synthetic) mutant thereof include, but are not limited to, 5' or 3' truncated nucleotide sequences, or sequences with an introduced in frame startcodon or stopcodon. Also, two or more such parts or fragments of one or more nucleotide sequences of the invention may be suitably combined (e.g. ligated in frame) to provide a further nucleotide sequence of the invention.
- 30

Preferably, any such parts or fragments will be such that they comprise at least one continuous stretch of at least 100 nucleotides, preferably at least 250 nucleotides, more preferably at least 500 nucleotides, even more preferably more than 100 nucleotides, of the nucleotide sequences of SEQ ID NO: 1.

5 Also, it is expected that - based upon the disclosure herein - the skilled person will be able to identify, derive or isolate natural "mutants" (as mentioned above) of the nucleotide sequences of SEQ ID NO: 1. from (other individuals of) the same species (for example from an individual of a different strain or line, including but not limited to mutant strains or lines). It is also expected that - based
10 upon the disclosure herein - the skilled person will be able to provide or derive synthetic mutants (as defined hereinabove) of the nucleotide sequences of SEQ ID NO: 1. It is also expected that - based upon the disclosure herein - the skilled person will be able to provide or derive polypeptide having (as defined hereinabove) polypeptide sequences of SEQ ID NO: 2 by means of protein
15 expression. In one specific embodiment, the mutant is such that it encodes the nucleotide sequence of SEQ ID NO: 1 or a part or fragment thereof.

Preferably, any mutants as described herein will have one or more, and preferably all, of the structural characteristics or conserved features referred to below for the nucleotide sequences of SEQ ID NO: 1.

20 Also, any mutants, parts or fragments as described herein will preferably have a degree of "sequence identity", at the nucleotide level, with the nucleotide sequences of SEQ ID NO: 1, of at least 75%, preferably at least 80%, more preferably at least 85%, and in particular more than 90%, and up to 95% or more.

For this purpose, the percentage of "sequence identity" between a given
25 nucleotide sequence and the nucleotide sequences of SEQ ID NO: 1, may be calculated by dividing the number of nucleotides in the given nucleotide sequence that are identical to the nucleotide at the corresponding position in the nucleotide sequences of SEQ ID NO: 1, by the total number of nucleotides in the given nucleotide sequence and multiplying by 100%, in which each deletion, insertion,
30 substitution or addition of a nucleotide - compared to the sequences of SEQ ID NO: 1, - is considered as a difference at a single nucleotide position.

Alternatively, computer programs for determining sequence identity are publicly available. A preferred computer program for determining sequence identity is the program in Geneworks v 2.5 (Intelligenetics Inc, Mountain View CA), which uses a progressive alignment procedure similar to FASTA. Preferably
5 the parameters used with the Geneworks program are: cost to open gap = 50, lengthen gap = 100, minimum diagonal length = 4, maximum diagonal offset = 125. Other computer program methods to determine identity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, FASTA
10 (Atschul, S.F. et al., J. Molec. Biol. 215: 403-410 (1990)) and VectorNTI (InforMax Inc., Bethesda, MD). The BLAST X program is publicly available from NCBI (blast@ncbi.nlm.nih.gov) and other sources (BLAST Manual, Altschul et al., NCBI NLM NIH, Bethesda, MD 20894; Altschul et al., J. Mol. Biol. 215: 403-410 (1990)), Vector NTI Suite Version 6 available from Informax Inc. North
15 Bethesda, MD.

Also, in a preferred aspect, any mutants, parts or fragments as described herein will encode proteins or polypeptides having biological activity that is essentially similar to the biological activity described above for the sequences of SEQ ID NO:, i.e. to a degree of at least 50 %, preferably at least 75%, and up to
20 90%, as measured by the assay mentioned above.

Any mutants, parts or fragments as described herein are preferably such that they are capable of hybridizing with the nucleotide sequences of SEQ ID NO: 1, i.e. under conditions of "moderate stringency", and preferably under conditions of "high stringency". Such conditions will be clear to the skilled person, for
25 example from the standard handbooks, such as Sambrook et al. and Ausubel et al., mentioned above, as well as in EP 0 967 284, EP 1 085 089 or WO 00/55318.

It is also within the scope of the invention to use a fusion of a nucleotide sequence of the invention (as described above) with one or more further nucleotide sequence(s), including but not limited to one or more coding sequences, non-
30 coding sequences or regulatory sequences. Preferably, in such fusions, the one or more further nucleotide sequences are operably connected (as described below) to the nucleotide sequence of the invention (for example so that, when the further

nucleotide sequence is a coding sequence, the nucleotide fusion encodes a protein fusion as described below).

In another embodiment, the invention relates to an antisense molecule against a nucleotide sequence of the invention.

5 A nucleic acid, preferably in (essentially) isolated form, can be used to encode or express an amino acid sequence, for example, the amino acid sequence of SEQ ID NO: 2.

On the basis of the above, and although the invention is not specifically limited to any specific explanation or mechanism, the nucleotide sequences of
10 some embodiments of the invention encode proteins that have (biological) activity as a myosin light chain kinase. In particular, the present invention has shown activity as a myosin light chain kinase from insects of the order *Hemiptera*, which are aphids, leafhoppers, whiteflies, scales and true bugs that have mouthparts adapted to piercing and sucking.

15 As is known in the art, biological activity of this kind can be measured using standard assay techniques, for example, through competition with a labeled, known ligand for binding sites; by guanosine 5'-[γ -³⁵S]-triphosphate binding to the kinase; by fluorescent assays based on protein interactions such as fluorescence resonance energy transfer, time resolved fluorescence or fluorometric or
20 colorimetric reporter assays; or any technology suitable for assaying MLCK proteins (see Kasturi et al.; Lei et al.; and Heierhorst et al.).

Another embodiment of the invention relates to a nucleic acid probe that is capable of hybridizing with a nucleotide sequence of the invention under conditions of moderate stringency, preferably under conditions of high stringency,
25 and in particular under stringent conditions (all as described above). Such nucleotide probes may for instance be used for detecting or isolating a nucleotide sequence of the invention or as a primer for amplifying a nucleotide sequence of the invention; all using techniques known per se, for which reference is again made to the general handbooks such as Sambrook et al. and Ausubel et al., mentioned
30 above.

Preferably, when to be used for detecting or isolating another nucleotide sequence of the invention, such a nucleotide probe will usually have a length of

between 15 and 100 nucleotides, and preferably between 20 and 80 nucleotides. When used as a primer for amplification, such a nucleotide probe will have a length of between 25 and 75 nucleotides, and preferably between 20 and 40 nucleotides.

5 Generally, such probes can be designed by the skilled person starting from a nucleotide sequence of the invention - and in particular the sequences of SEQ ID NO: 1 - optionally using a suitable computer algorithm. Also, as will be clear to the skilled person, such probes may be degenerate probes.

10 In a further aspect, the invention relates to methods for preparing mutants and genetic constructs of the nucleotide sequences of the present invention.

Natural mutants of the nucleotide sequences of the present invention may be obtained in a manner essentially analogous to the method described in the Experimental Part, or alternatively by:

- 15 - construction of a DNA library from the species of interest in an appropriate expression vector system, followed by direct expression of the mutant sequence;
 - 20 - construction of a DNA library from the species of interest in an appropriate expression vector system, followed by screening of said library with a probe of the invention (as described below) or with a nucleotide sequence of the invention;
 - isolation of mRNA that encodes the mutant sequence from the species of interest, followed by cDNA synthesis using reverse transcriptase;
- or by any other suitable method(s) or technique(s) known per se, for which reference is for instance made to the standard handbooks, such as Sambrook et al.,
- 25 "Molecular Cloning: A Laboratory Manual" (2nd.ed.), Vols. 1-3, Cold Spring Harbor Laboratory Press (1989) and F. Ausubel et al., "Current protocols in molecular biology", Green Publishing and Wiley Interscience, New York (1987).

30 Techniques for generating such synthetic sequences of the nucleotide sequences of the present invention will be clear to the skilled person and may for instance include, but are not limited to, automated DNA synthesis; site-directed mutagenesis; combining two or more parts of one or more naturally occurring sequences, introduction of mutations that lead to the expression of a truncated

expression product; introduction of one or more restriction sites (e.g. to create cassettes or regions that may easily be digested or ligated using suitable restriction enzymes), and the introduction of mutations by means of a PCR reaction using one or more "mismatched" primers. These and other techniques will be clear to the skilled person, and reference is again made to the standard handbooks, such as Sambrook et al. and Ausubel et al., mentioned above.

The invention will now be further illustrated by means of the following non-limiting Experimental Part.

10 Experimental Part:

Example 1 – Myosin Light Chain Kinase Sequence Identifications

Materials and Methods.

1. Isolation of poly(A⁺) RNA.

15

Cotton aphids were collected from cotton plants and placed in ice-chilled glass centrifuge tubes which had been cleaned and baked for 6 hours at 180°C prior to use. Aliquots of approximately 0.3 gram of cotton aphids was used for isolation of poly(A⁺) RNA and the remaining stored at -70 °C for future use .

20

In general, the RNA was isolated using QuickPrep mRNA Purification kit (Amersham Pharmacia biotech, Piscataway, NJ) according to the manufacturer's instruction. Specifically, to a 0.3 gram aliquot of cotton aphid was added 1.5 ml of a chilled extraction buffer (contained in the QuickPrep mRNA Purification kit).

25 Upon completion of addition, the mixture was homogenized in the Braun homogenizer until a uniform suspension formed. After homogenization, 3.0 ml of elution buffer (contained in the QuickPrep mRNA Purification kit) was added. The resulting mixture was homogenized briefly in the Braun homogenizer and then centrifuged at ambient temperature at approximately 12000 xg for ten minutes.

30 The resulting supernatant was collected, applied to the resin of a oligo(dT)-cellulose spun column (contained in the QuickPrep mRNA Purification kit), and washed with high salt and low salt buffers (contained in the QuickPrep mRNA

Purification kit). The bound poly(A⁺) RNA was eluted with three 0.25 ml portions of elution buffer pre-warmed to 65°C. To 0.5 mL of the elute was added 50 ml of an aqueous potassium acetate solution, 10 ml of a glycogen solution, and 1 ml of 95% ethanol. The resulting mixture was stored at -20°C for one hour and then
5 centrifuged at maximum speed. The resulting precipitated poly(A⁺) RNA was collected and then dissolved in 50 ml of the aqueous 0.1% DEPC solution. The resulting solution was stored at -80°C until use.

2. Design of primers.

10

Oligo (version 6.0) software was used to design primers based on sequence information from FMC's proprietary *Aphis gossypii* Expressed Sequencing Tag ("EST") library. Bioinformatics research indicated that two sequences in the library were the partial transcripts of target gene and flanked the region of interest,
15 including the catalytic domain of MLCK. Two pairs of primers were selected and their sequences are listed in the following:

sense primer F1: AGTGGACAGCGCAATTATCA, (SEQ ID NO: 3)
antisense primer R1: GTTACCGTAGCCGATGTCAGA, (SEQ ID NO: 4)
sense primer F2: GAATTTAGAGTGTACGCTGAA, (SEQ ID NO: 5)
20 antisense primer R2: TACTGGAGGCAAGTCGTTTC. (SEQ ID NO: 6)

3. Reverse Transcription and PCR amplification (RT-PCR).

Generally, RT-PCR was done using the ThermoscriptTM RT-PCR system
25 (Invitrogen, Carlsbad, CA). Specifically, to a 20 µl reaction vessel was added 0.3 µg of cotton aphid poly(A⁺) RNA, 1 µl of ThermoscriptTM reverse transcriptase, 1 µl of random hexamer (50 ng/ul), 4 µl 5x cDNA Synthesis Buffer, 1 µl RNaseOUTTM, 1 µl 0.1 M DTT (all contained in the ThermoscriptTM RT-PCR system) and appropriate volume of DEPC-treated water to a final volume of 20 µl.
30 Upon completion of addition, the reverse transcription reaction was placed on a Geneamp[®] 9600 thermal cycler (available from Perkin-Elmer-ABI, Foster City,

CA) and held at 25°C for ten minutes. After this time, the reaction was heated to 50°C where it was held for 50 minutes. Upon completion of this period, the reverse transcription reaction was incubated at 85°C for 5 minutes to terminate the reaction. The reaction was stored at -20°C or used immediately for PCR reaction.

5 To set up PCR reactions, 2 µl of the template solutions (reverse transcription reaction or the resultant solution from first PCR) was transferred to a 50 µl reaction vessel, and 5 µl of 10X PCR buffer, 1.5 µl of 50 mM MgCl₂, 1 µl of 10 mM dNTP, 0.4 µl of Platinum Tag DNA polymerase (5 U/µl) (all contained in the Thermoscript™ RT-PCR system), 1 µl of 10 µM sense primer, 1 µl of 10 µM
10 antisense primer, and 38.1 µl of DEPC-treated water were added. The reaction was placed on a Perkin Elmer cycler (available from Perkin Elmer - ABI) and PCR amplifications were carried out using appropriate cycling condition depending on respective primer pairs.

The first round of PCR using reverse transcription reaction as template, as
15 well as F1 and R1 as primer pairs, was run using the following conditions: the reaction was first heated at 94°C for 5 min, then followed by 30 cycles of the PCR reaction: denaturing at 94°C for 45 seconds, annealing at 54.3°C for 45 seconds, and extension at 72°C for 3 minutes. The completion of cycling was followed by incubation at 72°C for 10 minutes. . The resulting PCR products were
20 characterized by agarose gel electrophoresis. At this time no PCR product band or only vague PCR product band was observed.

To enrich PCR product, secondary "nested" amplifications were carried out using 2 µl of the above PCR reaction as template, as well as F2 and R2 as primer pairs.

The PCR condition is identical to that of first round except annealing at 52.3°C.

25 PCR products were characterized by agarose gel electrophoresis. A PCR fragment of approximately 2.5kb was excised from the gel and purified using MinElute™ Gel Extraction Kit (Qiagen Inc., 28159 Avenue Stanford, Valencia, CA) and the resulting DNA was ligated into a cloning vector as described below.

4. Subcloning of RT-PCR product and sequencing.

PCR product was ligated into pCR II TOPO vector according to manufacturer's instruction. The resulting plasmid was sequenced using T7 or SP6 as sequencing primers.

CLAIMS:

1. An isolated nucleic acid molecule having a nucleic acid sequence selected from the group consisting of: a nucleic acid sequence that encodes a polypeptide sequence of SEQ ID NO: 2, and a fragment thereof having at least 10 nucleotides.
2. The nucleic acid molecule of claim 1 consisting of SEQ ID NO: 1 or a fragment thereof having at least 10 nucleotides.
3. The nucleic acid molecule of claim 2 consisting of SEQ ID NO: 1.
4. The nucleic acid molecule of claim 1 consisting of a fragment of SEQ ID NO: 1 having at least 10 nucleotides.
5. The nucleic acid molecule of claim 1 consisting of a fragment of SEQ ID NO: 1 having 12-150 nucleotides.
6. The nucleic acid molecule of claim 1 consisting of a fragment of SEQ ID NO: 1 having 15-50 nucleotides.
7. A recombinant vector comprising a nucleic acid molecule of claim 1.
8. An isolated polypeptide molecule consisting of SEQ ID NO: 2 or a fragment thereof having at least 10 amino acids.
9. The polypeptide molecule of claim 8 consisting of SEQ ID NO: 2.
10. The polypeptide molecule of claim 8 consisting of a fragment of SEQ ID NO: 2 having at least 10 amino acids.

11. The polypeptide molecule of claim 8 consisting of a fragment of SEQ ID NO: 2 having 12-150 amino acids.
12. The polypeptide molecule of claim 8 consisting of a fragment of SEQ ID NO: 2 having 15-50 amino acids.

SEQUENCE LISTING

<110> FMC Corporation
Chen, Ruihua
Halling, Blaik P.
Chaguturu, Munirathan K.
Allenza, Paul
Yuhua, Debra A.

<120> Hemipteran Myosin Light Chain Kinase

<130> 60289-PCT

<140> To be assigned

<141> 2003-09-18

<150> 60/413,720

<151> 2002-09-26

<160> 1

<170> PatentIn version 3.2

<210> 1

<211> 2517

<212> DNA

<213> Aphis gossypii

<400> SEQ ID NO: 1:

gaatttagag tgtacgctga aaatgtgtat ggtagaagta aacctagtga agtatcacct	60
attgtaaaaa caaaagagtt gttgaaaaaa ccaccaaaaa ctaaactgta cgaagttgat	120
gaaactggca aaaaaattag aggaaaagca gatggcaata ttaaagatta cgaccaatat	180
gtttttgaca tttattcaaa atacatacca caaccagtgg atattaaaac acaatccgta	240
tatgattatt atgacatatt agaagaaatc ggaactgggtg catttggagt agtacaccgt	300
tgtagggaac gtaaaactgg aaatattttt gctgccaaat ttataccagt agcacataat	360
gttgaaaaag aattaattaa aaaagaaatt gacataatga accaacttca tcatccgaaa	420
ttgatcaatt tgcgatgatc ttctgaagat gaagatgaaa tgggtcttaat attcgaattt	480
ttgtctggag gagagctatt tgaaaggatc acctcagaag gatactcaat gtccgaagca	540
gaagtgatca actatatgcg acagatatgt gaagctatta agcatatgca tgaaagaaat	600
atcattcatt tagatatcaa accagaaaat ataatgtgcc agacaaagaa gagttcaa	660
gtaaaactca tcgatttttg attggcaacg aagttggatc ctaacgaaat cgttaagata	720
tcgacgggaa ctgctgagtt tgcgggtcca gaaatagttg aaagagaacc agttggtttc	780
tatacagaca tgtgggctgt tgggtgtctt gcatatgttc ttctgagtgg gctgtcacca	840
ttcgcaggag aaaacgacgt agagacgctt aaaaacgtga aagcttgtga ctgggacttt	900
gatgaagata cctttaacat agtttcagac gaaggaaaag attttatcag acgacttttg	960
attaaaaaca aagaaaaacg aatgacagct cacgaatgtt taatacatcc ttggctgatg	1020

ggagaccact ccgatcgtag agctgcactc aactcgtcca attacacaaa aatcagagat 1080
 caaatcgcga aaaaatacag tgattgggat tcgtttgtct taccacttgg aagaatatca 1140
 gaatacagtg ctctcagaaa gcttatggta gagaaatata aaatatacga aagctcgttt 1200
 gatcggcgac aagcagctcc acggttcggt attaagcctc aaagtgcatt ctgctacgaa 1260
 ggacaaagtg tcaagttcta ctgtcgtggt attgctgtag cacaaccgac attgtcatgg 1320
 ttccataata acgaagaatt aagacaaagt gttaaattca tgaagcgata tgctgggtgaa 1380
 gattacacgt tcattatcaa tagagctaag cttgatgata gaggagaata tataataaga 1440
 gctgaaaata cctatggcta tagggaagaa gtcgtattcc tcaacgtaca acctttgcca 1500
 aaagcagcac cggatatacag acatgaagtc caacaagtca gaagacgaga accactcgct 1560
 aatacatatt atatcgaaga gaaggaaagt gcaccaaatt tcaccttctt attacgacct 1620
 cgtgtcatatc aaatacatca aacttgcaag ttactgtgct gttaaagtgg cacgccaata 1680
 ccaactatac aatgggttcag aggaaccaa gagctatcta agcgtgatta caccattacc 1740
 catacggatg gtgtgattac attggaaatt attgactgca agcctgaaga ctcaggcaaa 1800
 tatcgtctgtg ttgccactaa tgtgcacggc acagacgaaa ccagctgcgt agtgattgta 1860
 gaaggtactg aacaaagcca agagcaggca gagttatcac ataatttact tcaactcagat 1920
 cgcaggtaca ccgatcagca tcatttcaga cccgcgcaa cggtcattac caagcgcacc 1980
 gccatcactt ccaacgtgca cggaagcagt tcggtgtctt caaaccaatc catcaccacc 2040
 aactcatcaa cgaaaatcag cgacacgacc gttacctcaa ccgacaggaa gagcgtcaaa 2100
 aaatacggca ataaactgaa cgcgattgga agtccgtcaa gatcccgtag ttctacaaaa 2160
 gaattaagat tatcaccgga tgaagccatg tgccctccgg acttttctac tcgcttagtc 2220
 gatacatctg tcaatgacgg acagtcgcta gaacttgatg gtaaagtac cggcgatccg 2280
 gagccacaaa tcacatgggt aaagaacgga aaagctatca gttcatctaa cgtcttagat 2340
 ctgaaatata aaaaccgatt agcgacgttg aagatcaatg aagtattccc cgaagatgct 2400
 ggagaatata tctgcaaagc taccaactcg ttgggaatga aggaacaag ttgcaaactc 2460
 acagtcaaag ctgtggacgt atccaaaaac aaaagccgaa acgacttgcc tccagta 2517

<210> 2
 <211> 839
 <212> PRT
 <213> *Aphis gossypii*

<400> SEQ ID. NO: 2:

Glu Phe Arg Val Tyr Ala Glu Asn Val Tyr Gly Arg Ser Lys Pro Ser
 1 5 10 15

Glu Val Ser Pro Ile Val Lys Thr Lys Glu Leu Leu Lys Lys Pro Pro
 20 25 30

Lys Thr Lys Arg Tyr Glu Val Asp Glu Thr Gly Lys Lys Ile Arg Gly
 35 40 45
 Lys Ala Asp Gly Asn Ile Lys Asp Tyr Asp Gln Tyr Val Phe Asp Ile
 50 55 60
 Tyr Ser Lys Tyr Ile Pro Gln Pro Val Asp Ile Lys Thr Gln Ser Val
 65 70 75 80
 Tyr Asp Tyr Tyr Asp Ile Leu Glu Glu Ile Gly Thr Gly Ala Phe Gly
 85 90 95
 Val Val His Arg Cys Arg Glu Arg Lys Thr Gly Asn Ile Phe Ala Ala
 100 105 110
 Lys Phe Ile Pro Val Ala His Asn Val Glu Lys Glu Leu Ile Lys Lys
 115 120 125
 Glu Ile Asp Ile Met Asn Gln Leu His His Pro Lys Leu Ile Asn Leu
 130 135 140
 His Asp Ala Phe Glu Asp Glu Asp Glu Met Val Leu Ile Phe Glu Phe
 145 150 155 160
 Leu Ser Gly Gly Glu Leu Phe Glu Arg Ile Thr Ser Glu Gly Tyr Ser
 165 170 175
 Met Ser Glu Ala Glu Val Ile Asn Tyr Met Arg Gln Ile Cys Glu Ala
 180 185 190
 Ile Lys His Met His Glu Arg Asn Ile Ile His Leu Asp Ile Lys Pro
 195 200 205
 Glu Asn Ile Met Cys Gln Thr Lys Lys Ser Ser Asn Val Lys Leu Ile
 210 215 220
 Asp Phe Gly Leu Ala Thr Lys Leu Asp Pro Asn Glu Ile Val Lys Ile
 225 230 235 240
 Ser Thr Gly Thr Ala Glu Phe Ala Ala Pro Glu Ile Val Glu Arg Glu
 245 250 255
 Pro Val Gly Phe Tyr Thr Asp Met Trp Ala Val Gly Val Leu Ala Tyr
 260 265 270
 Val Leu Leu Ser Gly Leu Ser Pro Phe Ala Gly Glu Asn Asp Val Glu
 275 280 285
 Thr Leu Lys Asn Val Lys Ala Cys Asp Trp Asp Phe Asp Glu Asp Thr
 290 295 300
 Phe Asn Ile Val Ser Asp Glu Gly Lys Asp Phe Ile Arg Arg Leu Leu
 305 310 315 320
 Ile Lys Asn Lys Glu Lys Arg Met Thr Ala His Glu Cys Leu Ile His
 325 330 335
 Pro Trp Leu Met Gly Asp His Ser Asp Arg Thr Ala Ala Leu Asn Ser
 340 345 350
 Ser Asn Tyr Thr Lys Ile Arg Asp Gln Ile Arg Lys Lys Tyr Ser Asp
 355 360 365

Trp Asp Ser Phe Ala Leu Pro Leu Gly Arg Ile Ser Glu Tyr Ser Ala
 370 375 380
 Leu Arg Lys Leu Met Val Glu Lys Tyr Lys Ile Tyr Glu Ser Ser Phe
 385 390 395 400
 Asp Arg Arg Gln Ala Ala Pro Arg Phe Val Ile Lys Pro Gln Ser Ala
 405 410 415
 Phe Cys Tyr Glu Gly Gln Ser Val Lys Phe Tyr Cys Arg Val Ile Ala
 420 425 430
 Val Ala Gln Pro Thr Leu Ser Trp Phe His Asn Asn Glu Glu Leu Arg
 435 440 445
 Gln Ser Val Lys Phe Met Lys Arg Tyr Ala Gly Glu Asp Tyr Thr Phe
 450 455 460
 Ile Ile Asn Arg Ala Lys Leu Asp Asp Arg Gly Glu Tyr Ile Ile Arg
 465 470 475 480
 Ala Glu Asn Thr Tyr Gly Tyr Arg Glu Glu Val Val Phe Leu Asn Val
 485 490 495
 Gln Pro Leu Pro Lys Ala Ala Pro Val Tyr Arg His Glu Val Gln Gln
 500 505 510
 Val Arg Arg Arg Glu Pro Leu Ala Asn Thr Tyr Tyr Ile Glu Glu Lys
 515 520 525
 Glu Ser Ala Pro Asn Phe Thr Phe Leu Leu Arg Pro Arg Val Ile Gln
 530 535 540
 Ile His Gln Thr Cys Lys Leu Leu Cys Cys Leu Ser Gly Thr Pro Ile
 545 550 555 560
 Pro Thr Ile Gln Trp Phe Arg Gly Thr Lys Glu Leu Ser Lys Arg Asp
 565 570 575
 Tyr Thr Ile Thr His Thr Asp Gly Val Ile Thr Leu Glu Ile Ile Asp
 580 585 590
 Cys Lys Pro Glu Asp Ser Gly Lys Tyr Arg Cys Val Ala Thr Asn Val
 595 600 605
 His Gly Thr Asp Glu Thr Ser Cys Val Val Ile Val Glu Gly Thr Glu
 610 615 620
 Gln Ser Gln Glu Gln Ala Glu Leu Ser His Asn Leu Leu His Ser Asp
 625 630 635 640
 Arg Arg Tyr Thr Asp Gln His His Phe Arg Pro Ala Pro Thr Val Ile
 645 650 655
 Thr Lys Arg Thr Ala Ile Thr Ser Asn Val His Gly Ser Ser Ser Val
 660 665 670
 Ser Ser Asn Gln Ser Ile Thr Thr Asn Ser Ser Thr Lys Ile Ser Asp
 675 680 685
 Thr Thr Val Thr Ser Thr Asp Arg Lys Ser Val Lys Lys Tyr Gly Asn
 690 695 700

Lys Leu Asn Ala Ile Gly Ser Pro Ser Arg Ser Arg Ser Ser Thr Lys
705 710 715 720

Glu Leu Arg Leu Ser Pro Asp Glu Ala Met Cys Pro Pro Asp Phe Ser
725 730 735

Thr Arg Leu Val Asp Thr Ser Val Asn Asp Gly Gln Ser Leu Glu Leu
740 745 750

Val Cys Lys Val Thr Gly Asp Pro Glu Pro Gln Ile Thr Trp Leu Lys
755 760 765

Asn Gly Lys Ala Ile Ser Ser Ser Asn Val Leu Asp Leu Lys Tyr Lys
770 775 780

Asn Arg Leu Ala Thr Leu Lys Ile Asn Glu Val Phe Pro Glu Asp Ala
785 790 795 800

Gly Glu Tyr Ile Cys Lys Ala Thr Asn Ser Leu Gly Met Lys Glu Thr
805 810 815

Ser Cys Lys Leu Thr Val Lys Ala Val Asp Val Ser Lys Asn Lys Ser
820 825 830

Arg Asn Asp Leu Pro Pro Val
835

<210> 3
<211> 1
<212> DNA
<213> sense primer F1

<400> SEQ ID NO: 3:

AGTGGACAGCGCAATTATCA 20

<210> 4
<211> 1
<212> DNA
<213> antisense primer R1

<400> SEQ ID NO: 4:

GTTACCGTAGCCGATGTCAGA 21

<210> 5
<211> 1
<212> DNA
<213> sense primer F2

<400> SEQ ID NO: 5:

GAATTTAGAGTGTACGCTGAA 21

<210> 6
<211> 1
<212> DNA
<213> antisense primer R2

<400> SEQ ID NO: 6:

TACTGGAGGCAAGTCGTTTC 20

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
8 April 2004 (08.04.2004)

PCT

(10) International Publication Number
WO 2004/029577 A3

(51) International Patent Classification⁷: **C12N 9/12**,
15/00, C12P 21/06, C07K 1/00, C07H 21/02, 21/04

(74) Agents: SHEEHAN, John, M. et al.; FMC Corporation,
1735 Market Street, Philadelphia, PA 19103 (US).

(21) International Application Number:
PCT/US2003/029901

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT,
RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
18 September 2003 (18.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/413,720 26 September 2002 (26.09.2002) US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): FMC
CORPORATION [US/US]; 1735 Market Street, Philadel-
phia, PA 19103 (US).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): CHEN, Ruihua
[CN/US]; 16 Labrador Drive, Kendall Park, NJ 08824
(US). CHAGUTURU, Munirathnam, K. [US/US]; 3
Edith Court, West Windsor, NJ 08550 (US). YUHAS,
Debra [US/US]; 622 Hanover Drive, Wrightstown, NJ
08562 (US). ALLENZA, Paul [US/US]; 16 Pleasant View
Way, Flemington, NJ 08822 (US). HALLING, Blaik, P.
[US/US]; 384 Chase Road, Newtown, PA 18940 (US).

(88) Date of publication of the international search report:
1 July 2004

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: HEMIPTERAN MYOSIN LIGHT CHAIN KINASE

(57) Abstract: Novel nucleic acid sequences encoding hemipteran myosin light chain kinases are disclosed. Isolated hemipteran myosin light chain kinases are also disclosed.

WO 2004/029577 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US03/29901

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12N 9/12, 15/00; C12P 21/06; C07K 1/00; C07H 21/02, 21/04

US CL : 435/194, 320.1, 69.1; 536/23.1, 23.2; 530/350

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/194, 320.1, 69.1; 536/23.1, 23.2; 530/350

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
MEDLINE EMBASE BIOSIS BIOTECHDS SCISEARCH HCAPLUS NTIS LIFESCI BRS/EAST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Database GenEMBL, No. AY047563, Lawrence Berkeley National Laboratory, (Berkeley, CA 94720, USA) STAPLETON et al. 'Direct submission' 16 August 2001, see specially residues matching bases 319-338 of SEQ ID NO:1.	1-2, 4-7
X	WO 01/71042 A2 (PE CORPORATION (NY)) 27 September 2001 (27.09.2001), see residues matching amino acids 85-109 of SEQ ID NO:2.	8, 10-12



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier application or patent published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T"

later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X"

document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y"

document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&"

document member of the same patent family

Date of the actual completion of the international search

16 March 2004 (16.03.2004)

Date of mailing of the international search report

12 MAY 2004

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US

Commissioner for Patents

P.O. Box 1450

Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Maryam Monshipouri

Telephone No. 703 308-0196

J. Roberts for

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.